Saturday, 15 August 2020


Gilead, Teva to settle patent case of HIV drug

21 February 2013 | News | By BioSpectrum Bureau

Gilead, Teva to settle patent case of HIV and Hepatitis drug Viread

Gilead, Teva to settle patent case of HIV and Hepatitis drug Viread

Singapore: Biopharmaceutical companies Gilead Sciences and Teva Pharmaceuticals have decided to settle the ongoing patent litigation concerning the patents protecting Viread (tenofovir disoproxil fumarate), a treatment for HIV infection and chronic hepatitis B. Under the terms of the settlement, Teva will be allowed to launch a generic version of Viread on December 15, 2017.

"We believe strongly in the validity of our intellectual property," said Dr John Milligan, Gilead's president and CEO. "This settlement, however, removes some uncertainty and minimizes further distraction and investment of human and financial resources associated with this litigation."

The trial in the litigation, which was scheduled to begin on February 20, 2013, in the District Court for the Southern District of New York, has been adjourned pending completion of activities necessary to finalize the settlement.


Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account




Podcast

 

Survey Box

Should we be cautious of viewing COVID-19 vaccine as silver bullet?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls